Annual report pursuant to Section 13 and 15(d)

Merger, Allocation of Purchase Price (Details)

v3.22.1
Merger, Allocation of Purchase Price (Details) - USD ($)
$ in Thousands
12 Months Ended
Nov. 05, 2020
Dec. 31, 2021
Dec. 31, 2020
Allocation of Purchase Price [Abstract]      
Cash acquired   $ 0 $ 2,014
IPR&D   $ 0 $ 10,502
Rexahn [Member]      
Allocation of Purchase Price [Abstract]      
Cash acquired $ 2,014    
Net assets assumed 68    
IPR&D [1] 8,376    
Purchase price $ 10,458    
[1] Represents the pre-Merger research and development projects of Rexahn which were in-process, but not yet completed, and which the Company may advance post-Merger.  This includes the development of RX-3117, RX-0301 and RX-0047. Current accounting standards require that the fair value of IPR&D projects acquired in an asset acquisition with no alternative future use be allocated a portion of the consideration transferred and charged to expense on the acquisition date. The acquired assets did not have outputs or employees.